论文部分内容阅读
目的:观察小剂量重组人类红细胞生成素治疗老年肾性贫血的疗效、副反应,并与常规剂量重组人类红细胞生成素进行比较。方法:将36例老年终末期肾病患者随机分为小剂量组(A组)和常规剂量组(B组),治疗3个月后,观察红细胞压积、生活质量的变化及血压升高、血栓性疾病等副反应。结果:2组红细胞压积均有显著升高,生活质量明显改善。A组20例仅发生1例血压升高,B组16例中有5例发生血压升高,同时有1例发生动静脉内瘘阻塞。结论:使用小剂量重组人类红细胞生成素是治疗老年肾性贫血的安全、有效、可行的方法。
OBJECTIVE: To observe the curative effect and side effects of low-dose recombinant human erythropoietin in the treatment of senile renal anemia, and to compare with conventional doses of recombinant human erythropoietin. Methods: Thirty-six elderly patients with end-stage renal disease were randomly divided into low-dose group (group A) and conventional dose group (group B). After 3 months of treatment, hematocrit, quality of life, blood pressure, Sexually transmitted diseases and other side effects. Results: The two groups of hematocrit were significantly increased, quality of life improved significantly. A group of 20 cases occurred only one case of hypertension, B group of 16 cases in 5 cases of hypertension, while 1 case of arteriovenous fistula occlusion. Conclusion: The use of low-dose recombinant human erythropoietin is a safe, effective and feasible method for the treatment of senile renal anemia.